JAK1 and vitiligo: JAK inhibitors (JAKi), such as tofacitinib (a pan JAKi) and ruxolitinib (selectivity for JAK1 and JAK2), have apparently reversed vitiligo in some case reports [34], and ongoing clinical trials [60, 61].